Breaking News

Novozymes, Janssen In VELTIS Technology Pact

By Kristin Brooks | March 21, 2014

Will evaluate VELTIS technology for potential drug candidates

Novozymes Biopharma has entered a collaboration with Janssen Research & Development, LLC under which Janssen will evaluate Novozymes’s engineered albumin-based VELTIS technology for potential drug candidates. Novozymes' VELTIS technology represents a series of engineered human albumins that in combination with a drug candidate, offers the potential for control of the therapeutic half-life, which allows for reducing the dosing frequency of drugs from daily to every two weeks or monthly.
 
"We are delighted to be working with Janssen on this important collaboration," said Svend Licht, senior director, Novozymes Biopharma. "The VELTIS half-life extension technology can be linked to a broad range of drug candidates and the agreement is central in our continued strategy to demonstrate its potential to facilitate greater control across many therapeutic fields. The VELTIS platform is a transformative technology that offers real potential to revolutionize the delivery of treatments. Working with partners across a wide-range of medical conditions, we are continuing to highlight the benefits of the solution in improving the lives of patients."

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important